Literature DB >> 22961482

Foxp3 overexpression decreases sensitivity to chemotherapy in mouse Lewis lung cancer cells.

Chun Li1, Wei Yang, Xiaodong Gai, Yinglin Zhang, Yi Li, Haiying Fu.   

Abstract

Chemotherapy is the main strategy for the treatment of lung cancer. However, sensitivity to chemotherapy, one of the main factors affecting the survival rate of patients with lung cancer, is extremely poor. Forkhead box P3 (Foxp3) is the key regulatory gene for the development and function of CD4+CD25+ regulatory T cells (Tregs). Increased levels of Tregs and Foxp3 expression in the peripheral blood and tumour specimens of cancer patients are associated with tumour progression and poor prognosis. In addition, certain studies have suggested that Tregs may be resistant to conventional chemotherapy and thus, enhance tumour immune evasion. Previous studies have demonstrated that Foxp3 is also expressed within tumour cells and that it may mimic the function of Tregs. Currently, the correlation between the tumour cell expression of Foxp3 and sensitivity to chemotherapy is unclear. Therefore, it was hypothesised that Foxp3 causes resistance to chemotherapeutic agents in lung cancer cells and that it may consequently promote the progression of lung cancer. In the current study, the expression of Foxp3 in mouse Lewis lung cancer (LLC) cells was detected using RT-PCR and immunocytochemistry. The overexpression of Foxp3, which was accomplished by the transient transfection of recombinant pcDNA3.1-Foxp3 or empty plasmids into LLC cells, was confirmed by RT-PCR and western blot analysis. The inhibition of cell proliferation was measured using MTT assay. The expression of multidrug resistance protein 1 (mdr1) mRNA and its protein product, P-glycoprotein (P-gp), were detected by RT-PCR and flow cytometry, respectively. The results revealed that Foxp3 was expressed by LLC cells. The inhibitory rate of cell proliferation in Foxp3-overexpressing LLC cells compared with those transfected with an empty plasmid was significantly decreased following adriamycin (ADM) and mitomycin C (MMC) treatment. The IC50 values of ADM and MMC in Foxp3-overexpressing LLC cells were increased. The expression levels of mdr1 mRNA and P-gp were significantly upregulated in Foxp3 overexpressing LLC cells. These results suggest that Foxp3 reduces the sensitivity of LLC cells to ADM and MMC, thus promoting tumour progression, by upregulating the expression of mdr1 mRNA and P-gp.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961482     DOI: 10.3892/mmr.2012.1066

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

1.  A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.

Authors:  Qian Zhao; Wen Zhang; Zhifeng Ning; Xiufen Zhuang; Haizhen Lu; Jing Liang; Jie Li; Yu Zhang; Ying Dong; Youhui Zhang; Shuren Zhang; Shangmei Liu; Binlei Liu
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

Review 2.  Strategy to targeting the immune resistance and novel therapy in colorectal cancer.

Authors:  Wang Gang; Jun-Jie Wang; Rui Guan; Sun Yan; Feng Shi; Jia-Yan Zhang; Zi-Meng Li; Jing Gao; Xing-Li Fu
Journal:  Cancer Med       Date:  2018-04-15       Impact factor: 4.452

Review 3.  The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment.

Authors:  Yanghong Ni; Xiaoting Zhou; Jia Yang; Houhui Shi; Hongyi Li; Xia Zhao; Xuelei Ma
Journal:  Front Cell Dev Biol       Date:  2021-05-20

4.  FOXP3 facilitates the invasion and metastasis of non-small cell lung cancer cells through regulating VEGF, EMT and the Notch1/Hes1 pathway.

Authors:  Chun Li; Hefei Wang; Hui Fang; Chengyuan He; Yijie Pei; Xiaodong Gai
Journal:  Exp Ther Med       Date:  2021-07-06       Impact factor: 2.447

5.  Bioactive compounds from the roots of Asiasarum heterotropoides.

Authors:  Jun Lee; You Jin Lee; Se-Mi Oh; Jin-Mu Yi; No Soo Kim; Ok-Sun Bang
Journal:  Molecules       Date:  2013-12-23       Impact factor: 4.411

6.  Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy.

Authors:  Lujuan Han; Suli Dai; Zhirong Li; Cong Zhang; Sisi Wei; Ruinian Zhao; Hongtao Zhang; Lianmei Zhao; Baoen Shan
Journal:  J Exp Clin Cancer Res       Date:  2019-12-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.